GLP-1s after 50

Our readership skews older than the marketing in this category assumes, and the risk profile shifts with it.

This is not an argument against taking a GLP-1. Obesity carries serious risks of its own, and these medications work. It is an argument for going in with a specific set of questions — the ones a good clinician will raise anyway.

What the literature actually says

Published commentary notes that up to half of adults over 80 experience sarcopenia, and reviews have raised the specific concern that stopping treatment can bring fat regain outpacing lean-mass recovery. That is a body-composition outcome worse than the starting point, and it is not in anybody's sales copy.

What the concern actually is

Weight lost on a GLP-1 is not purely fat. Some of it is lean mass, and older adults are already more prone to losing muscle with age — sarcopenia. Published commentary in Endocrine News has noted that up to half of adults over 80 experience sarcopenia, and reviews in PMC have raised the specific concern that stopping treatment can bring rapid fat regain that outpaces lean-mass recovery, which would leave someone worse off in body composition than when they started.

The practical consequences that specialists point to are falls, frailty, reduced mobility and loss of independence — outcomes that matter more in your sixties than a number on a scale does. The Mayo Clinic, AARP, Ohio State and the AAMC have all published patient-facing material on this through 2025 and 2026.

Other things that matter more with age

• Constipation is close to universal on these drugs and is more of a problem if you are already prone to it.
• Dehydration. Appetite loss reduces drinking as well as eating, and older adults dehydrate faster with worse consequences.
• Any procedure involving sedation. Tell the anaesthetist you are on a GLP-1 well in advance — delayed stomach emptying raises aspiration risk and there is specific guidance on pausing beforehand.
• Existing medications. Insulin and sulfonylureas in particular often need adjusting; so can anything with a narrow therapeutic window.

The cost angle, since that is what we normally cover

If you are on Medicare, the $50-a-month programme starting July 2026 is likely to be cheaper and better supervised than anything you can buy for cash — see the Medicare briefing. If you are not, the programmes with the most clinical contact rather than the lowest price may be the better trade at this age.

None of this is medical advice and this page is not a substitute for a consultation. It is the list of things worth raising with a clinician who knows your history — and if a provider will not engage with these questions, that tells you something about the provider.